| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
Purity: ≥98%
Prasugrel Hydrochloride (formerly also known as CS-747, PCR 4099 and LY640315), a piperazine derivative, is a novel and potent thienopyridine ADP receptor (P2Y12) antagonist used for the reduction of thrombotic cardiovascular events. Prasugrel was also approved for use in Europe in February 2009. On July 10, 2009, the FDA approved the use of prasugrel for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome who are to be managed with PCI.
| Targets |
P2Y12 receptor on platelets. It is an irreversible antagonist. [1]
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
With an IC50 value of 1.8 μM, the active metabolite of prasugrel hydrochloride inhibits the in vitro platelet aggregation generated by adenosine ADP (10μM) in rat platelets[2]. In vivo, prasugrel hydrochloride exhibits a greater potency and works more quickly than clopidogrel. The active antiplatelet metabolite of prasugrel hydrochloride is produced by metabolic breakdown of the inactive prodrug in vivo. From the stomach, prasugrel hydrochloride is quickly absorbed. Maximum plasma levels of the active metabolite are reached within 1 hour following oral administration of standard-loading dosages of 60 mg, and maximal inhibition of platelet aggregation occurs within 1-2 hours[1].
Following oral administration, prasugrel is rapidly absorbed and converted to its active metabolite, leading to a more rapid onset of action compared to clopidogrel. It achieves greater and more consistent platelet inhibition in individual patients, with less inter-individual variability. Its antiplatelet effect is more predictable than clopidogrel, partly because its metabolism is less affected by polymorphisms in CYP2C9 and CYP2C19 genes. The irreversible binding means its effect lasts for the lifetime of the platelet (7-10 days). In the phase III TRITON-TIMI 38 trial, in patients with acute coronary syndromes scheduled for percutaneous coronary intervention (PCI), prasugrel treatment resulted in a significantly better outcome for the composite of death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke compared to clopidogrel (hazard ratio 0.81, 95% confidence interval 0.73-0.90, P < 0.001). A significant reduction in stent thrombosis was also observed. [1] |
||
| Animal Protocol |
|
||
| ADME/Pharmacokinetics |
Prasugrel is an orally administered prodrug. It is metabolized in vivo to an active metabolite, which is responsible for its antiplatelet effect. The metabolism of prasugrel, unlike clopidogrel, is not significantly affected by common polymorphisms in CYP2C9 and CYP2C19 genes, leading to more predictable and higher levels of active metabolite production. This contributes to its more consistent and greater platelet inhibition. [1]
|
||
| Toxicity/Toxicokinetics |
Use of Prasugrel during Pregnancy and Lactation ◉ Overview of Use During Lactation
There is currently no publicly available information regarding the use of prasugrel during lactation. Until more data becomes available, lactating women should use prasugrel with caution, especially when breastfeeding newborns or premature infants. If a lactating woman uses prasugrel, the infant should be closely monitored for bruising and bleeding. ◉ Effects on Breastfed Infants As of the revision date, no relevant published information was found. ◉ Effects on Lactation and Breast Milk As of the revision date, no relevant published information was found. In the TRITON-TIMI 38 trial, the increased clinical efficacy of prasugrel over clopidogrel was achieved at the expense of an increased incidence of bleeding. The risk of bleeding outweighed the clinical benefit in specific patient subgroups: those with a previous history of stroke, the elderly (≥75 years), and those with a body weight of less than 60 kg. A higher incidence of adverse events related to colon cancer was also noted among patients treated with prasugrel in this study, though the reason was unclear and may be related to earlier detection of subclinical lesions due to increased bleeding. [1] Drug-drug interactions: The presence of a reversible P2Y12 antagonist like cangrelor can limit the ability of the prasugrel active metabolite to produce irreversible inhibition of platelet function if administered concurrently. This has important implications when switching patients between these therapies. [1] |
||
| References | |||
| Additional Infomation |
Prasugrel hydrochloride is the hydrochloride form of prasugrel, a thienopyridine antiplatelet drug with high oral bioavailability. After oral administration, the active metabolite of prasugrel targets and irreversibly binds to the platelet adenosine diphosphate (ADP) receptor, thereby blocking the binding of ADP to its receptor. This inhibits ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, fibrinogen binding to platelets, and platelet adhesion and aggregation. This leads to prolonged bleeding time. This product is a piperazine derivative and platelet aggregation inhibitor used to prevent thrombosis in patients with acute coronary syndrome, unstable angina, and myocardial infarction, as well as in patients undergoing percutaneous coronary intervention. See also: Prasugrel (containing the active ingredient).
Prasugrel is a thienopyridine and prodrug, succeeding ticlopidine and clopidogrel in this class. It was developed to overcome some of the limitations of clopidogrel, particularly the variability in patient response. It is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). In the UK, NICE recommends it as the preferred antiplatelet agent in patients with a low risk of bleeding who are undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI). A major factor limiting its widespread clinical use is its higher cost compared to generic clopidogrel. [1] |
| Exact Mass |
409.091
|
|---|---|
| CAS # |
389574-19-0
|
| Related CAS # |
Prasugrel;150322-43-3;Prasugrel (Maleic acid);389574-20-3;Prasugrel-d5;1127252-92-9
|
| PubChem CID |
10158453
|
| Appearance |
Light yellow to yellow solid powder
|
| Boiling Point |
493.5ºC at 760 mmHg
|
| Flash Point |
252.3℃
|
| LogP |
4.63
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
555
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1=CC=CC=C1C(C(C2CC2)=O)N3CCC4=C(C3)C=C(S4)OC(C)=O.Cl
|
| InChi Key |
JALHGCPDPSNJNY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H20FNO3S.ClH/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21;/h2-5,10,13,19H,6-9,11H2,1H3;1H
|
| Chemical Name |
Ethanone, 2-(2-(acetyloxy)-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-1-cyclopropyl-2-(2-fluorophenyl)-, hydrochloride
|
| Synonyms |
Prasugrel HydrochloridePrasugrel HClCS-747CS747CS 747PCR-4099PCR4099PCR 4099LY-640315LY640315LY 640315
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~41.67 mg/mL (~101.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04445623 | UNKNOWN STATUS | Drug: Prasugrel Hydrochloride 10 MG Oral Tablet Drug: Placebo |
COVID19 Thrombosis |
Azienda Ospedaliera Universitaria Integrata Verona | 2020-07 | Phase 3 |
| NCT00059215 | COMPLETEDWITH RESULTS | Drug: Prasugrel (CS-747) Drug: Clopidogrel |
Cardiovascular Diseases Heart Diseases |
Eli Lilly and Company | 2003-04 | Phase 2 |
| NCT05359224 | RECRUITING | Drug: Prasugrel group Drug: Clopidogrel group |
Intracranial Aneurysm | Yonsei University | 2022-06-13 | Phase 4 |
| NCT01852019 | COMPLETEDWITH RESULTS | Drug: Cangrelor Drug: Prasugrel |
Coronary Artery Disease | The Medicines Company | 2013-06 | Phase 2 |
| NCT02212028 | COMPLETEDWITH RESULTS | Drug: prasugrel | Coronary Artery Disease | University of Florida | 2014-10 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA